A critical and concise review of mass spectrometry applied to imaging in drug discovery

Goodwin, Richard J. A.; Takats, Zoltan; Bunch, Josephine

Type de document :

Article dans une revue scientifique: Article de synthèse/Review paper

DOI :

10.1177/2472555220941843

PMID :

32713279

URL permanente :

http://hdl.handle.net/20.500.12210/75174

Titre :

A critical and concise review of mass spectrometry applied to imaging in drug discovery

Auteur(s) :

Goodwin, Richard J. A. [Auteur]

Takats, Zoltan [Auteur]
Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U1192
Bunch, Josephine [Auteur]
Imperial College London

Titre de la revue :

Slas Discovery

Nom court de la revue :

SLAS Discov.

Numéro :

Pagination :

963-976

Date de publication :

2020-10

ISSN :

2472-5552

Mot(s)-clé(s) :

MALDI
imaging
MSI
mass spectrometry imaging
SIMS
DESI

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

During the past decade, mass spectrometry imaging (MSI) has become a robust and versatile methodology to support modern pharmaceutical research and development. The technologies provide data on the biodistribution, metabolism, ...
Lire la suite >During the past decade, mass spectrometry imaging (MSI) has become a robust and versatile methodology to support modern pharmaceutical research and development. The technologies provide data on the biodistribution, metabolism, and delivery of drugs in tissues, while also providing molecular maps of endogenous metabolites, lipids, and proteins. This allows researchers to make both pharmacokinetic and pharmacodynamic measurements at cellular resolution in tissue sections or clinical biopsies. Despite drug imaging within samples now playing a vital role within research and development (R&D) in leading pharmaceutical companies, however, the challenges in turning compounds into medicines continue to evolve as rapidly as the technologies used to discover them. The increasing cost of development of new and emerging therapeutic modalities, along with the associated risks of late-stage program attrition, means there is still an unmet need in our ability to address an increasing array of challenging bioanalytical questions within drug discovery. We require new capabilities and strategies of integrated imaging to provide context for fundamental disease-related biological questions that can also offer insights into specific project challenges. Integrated molecular imaging and advanced image analysis have the opportunity to provide a world-class capability that can be deployed on projects in which we cannot answer the question with our battery of established assays. Therefore, here we will provide an updated concise review of the use of MSI for drug discovery; we will also critically consider what is required to embed MSI into a wider evolving R&D landscape and allow long-lasting impact in the industry.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

INSERM
Université de Lille

Collections :

Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U1192

Date de dépôt :

2022-06-15T13:59:40Z
2023-03-08T11:51:24Z

Fichiers

2020-07-25-2472555220941843.pdf
Version éditeur
Accès restreint
Accéder au document

Numéro de version	Lien	Date de modification
2	20.500.12210/75174*	2023-03-08T11:46:56Z
1	20.500.12210/75174.1	2022-06-15T13:59:40Z

A critical and concise review of mass ...

BibTeX

CSV

Excel

RIS

Fichiers

Historique des modifications

A critical and concise review of mass ... BibTeX CSV Excel RIS

Fichiers

Historique des modifications

A critical and concise review of mass ...

BibTeX

CSV

Excel

RIS